MarginsXMarginsX
Home › Markets › Health Care › CANF

Can-Fite Biopharma Ltd (CANF)

CANF trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.56
+9.86% on the day
Market cap
$4.7M
Nano cap
Revenue · 2025
$405K
-39.9% on 2024
Net income · 2025
-$9.8M
-2426.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/0001213900-26-034447-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCANF on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001536196
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$405K
Net income-$9.8M
Operating income-$9.9M
Net margin-2426.7%
Operating margin-2456.8%
Revenue growth-39.9%
Cash$5.5M
Total assets$9.5M
P/E (computed)Net income was not positive
P/S (computed)11.7×

Warning signs

Cash runway
7.4 months
$5.5M cash at December 31, 2025
Share count, 1 year
-98.2%
2024-12-31 to 2025-12-31 · -93.6% over 3 years
Going-concern doubt
Yes
20-F filed March 26, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Evaluation of Substantial Doubt Raised In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern: - History of net losses of $ 9,828 , $ 7,880 and $ 7,634 for the years ended December 31, 2025, 2024 and 2023, respectively."
20-F 2026-03-26
Cash and burn$5.5M cash; operating cash flow -$2.2M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-20 on 2026-01-05Source 2026-01-05
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-25
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKost Forer Gabbay & Kasierer, Tel Aviv, IsraelPCAOB Form AP 2026-04-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$405K-$9.8M-$8.9M$5.5MNo debt tags$405K20-F 2026-03-26
FY 2024
2024-12-31
$674K-$7.9M-$7.6M$4.8MNo debt tags$674K20-F 2026-03-26
FY 2023
2023-12-31
$743K-$7.6M-$8.4M$4.3MNo debt tags$743K20-F 2026-03-26
FY 2022
2022-12-31
$810K-$10.2M-$10.8M$3.0MNo debt tags$810K20-F 2025-04-14
FY 2021
2021-12-31
$853K-$12.6M-$9.9M$4.4MNo debt tags$853K20-F 2023-03-30
FY 2020
2020-12-31
$763K-$14.4M-$12.1M$8.3MNo debt tags$763K20-F 2023-03-30
FY 2019
2019-12-31
$2.0M-$12.6M-$11.1M$2.7MNo debt tags$2.0M20-F 2022-03-24
FY 2018
2018-12-31
$3.8M-$6.6M-$4.2M$3.6MNo debt tags$3.8M20-F 2021-03-25

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-10-09
Latest annual report
ANNUAL REPORT
20-F2026-03-26
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-12

Source: SEC EDGAR submissions feed, 867 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-12.3%
1 month-27.2%
3 months-58.2%
Year to date-64.5%
1 year-80.8%
From 52-week high-81.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
PCSAProcessa Pharmaceuticals Inc.$1.72-7.53%$4.8M
PULMPulmatrix Inc.$1.33+2.31%$4.9M
SCNXScienture Holdings Inc.$2.99+3.10%$4.9M
CVKDCadrenal Therapeutics Inc.$1.40-7.28%$5.0M
NCNANuCana plc American Depositary Share$0.8631-7.46%$4.4M
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M
KPRXKiora Pharmaceuticals Inc.$0.9820-20.16%$4.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier